Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Siemens Fonds Invest GmbH

Siemens Fonds Invest GmbH grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 561.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,002 shares of the medical equipment provider's stock after acquiring an additional 12,735 shares during the period. Siemens Fonds Invest GmbH's holdings in Zimmer Biomet were worth $1,585,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ZBH. Stonebridge Financial Group LLC acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth $25,000. Menard Financial Group LLC bought a new position in shares of Zimmer Biomet during the fourth quarter worth about $30,000. Accredited Wealth Management LLC bought a new position in shares of Zimmer Biomet during the fourth quarter worth about $36,000. Kentucky Trust Co bought a new position in shares of Zimmer Biomet during the fourth quarter worth about $39,000. Finally, OFI Invest Asset Management bought a new position in Zimmer Biomet in the fourth quarter worth about $40,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Performance

ZBH traded down $1.22 during trading on Friday, hitting $92.12. 3,505,131 shares of the stock were exchanged, compared to its average volume of 1,800,204. The firm has a market capitalization of $18.23 billion, a P/E ratio of 20.70, a PEG ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.92 and a 1-year high of $116.71. The stock has a fifty day moving average price of $99.99 and a two-hundred day moving average price of $104.74. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The business had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. During the same quarter in the previous year, the company posted $1.94 earnings per share. The company's revenue for the quarter was up 1.1% compared to the same quarter last year. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.04%. Zimmer Biomet's dividend payout ratio (DPR) is 21.24%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This represents a 14.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 1.39% of the company's stock.

Analyst Upgrades and Downgrades

ZBH has been the topic of several analyst reports. Raymond James dropped their price target on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Robert W. Baird lowered their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Stifel Nicolaus set a $115.00 price objective on shares of Zimmer Biomet and gave the company a "buy" rating in a research note on Tuesday, May 6th. Barclays reduced their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Monday, February 10th. Finally, The Goldman Sachs Group cut their target price on shares of Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a research report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. According to MarketBeat, Zimmer Biomet presently has an average rating of "Hold" and a consensus price target of $111.53.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.